Comprehensive Genomic Profiling (CGP) in the U.S. - Medical Oncologist, Medium East-Coast IHN

A medical oncologist discusses the importance of CGP in cancer treatment decision-making, the need for efficient communication and support from test vendors, and current challenges with reimbursement. Clinical trial matching support is seen as beneficial, and biomarker testing should be included in CGP to avoid the need for multiple testing methods. They note that CGP is important for advanced stage tumors, especially those without defined markers. On a similar note, they also mention ongoing changes and additions to their CGP panel to accommodate rare mutations and clinical trial needs. The stakeholder acknowledges the reimbursement challenges associated with CGP testing and the need to limit the frequency of testing due to cost, highlighting the clinical utility of CGP as a pain point and suggesting that a blanket approach to testing may not be necessary. They suggest incorporating CGP into society guidelines and algorithms to ensure acceptance by payers and insurance companies. They also mention that newer technologies and AI can help reduce the turnaround time.

‍